X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Vertex will obtain a non-exclusive license for Editas Medicine’s Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of sickle cell disease and beta thalassemia, including Casgevy (exagamglogene autotemcel).
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Hematology Product Name: Casgevy
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 13, 2023
Details:
EDIT-301 consists of patient-derived CD34+ hematopoietic stem and progenitor cells edited at the gamma globin gene (HBG1 and HBG2) promoters, which demonstrated a sustained increase in fetal hemoglobin production in patients with with severe SCD and TDT.
Lead Product(s): EDIT-301,Busulfan
Therapeutic Area: Hematology Product Name: EDIT-301
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
The partnersip aims to support the scaling of EDIT-301, Editas Medicine’s experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), from approval to commercialization.
Lead Product(s): EDIT-301
Therapeutic Area: Hematology Product Name: EDIT-301
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Azzur Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 27, 2023
Details:
EDIT-301 consists of patient-derived CD34+ hematopoietic stem and progenitor cells edited at the gamma globin gene (HBG1 and HBG2) promoters, which demonstrated a sustained increase in fetal hemoglobin production in patients with with severe SCD and TDT.
Lead Product(s): EDIT-301,Busulfan
Therapeutic Area: Hematology Product Name: EDIT-301
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
Under the terms of the agreement, Shoreline will acquire EDIT-202, Editas Medicine’s preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors and an additional iNK program under development and certain related manufacturing technologies.
Lead Product(s): EDIT-202
Therapeutic Area: Oncology Product Name: EDIT-202
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Shoreline Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 19, 2023
Details:
EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
Lead Product(s): EDIT-301,Busulfan
Therapeutic Area: Genetic Disease Product Name: EDIT-301
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
EDIT-101 is a CRISPR/Cas9-based experimental medicine under investigation for the treatment of Leber congenital amaurosis 10 (LCA10), by deleting the IVS26 CEP290 mutant allele.
Lead Product(s): EDIT-101
Therapeutic Area: Rare Diseases and Disorders Product Name: EDIT-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
EDIT-103 is a CRISPR/Cas9-based experimental medicine in preclinical development for the treatment of rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP), a progressive form of retinal degeneration.
Lead Product(s): EDIT-103
Therapeutic Area: Genetic Disease Product Name: EDIT-103
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
Details:
EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
Lead Product(s): EDIT-301,Busulfan
Therapeutic Area: Genetic Disease Product Name: EDIT-301
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
By combining Editas’s gene editing technology with Immatics’ ACTallo® allogeneic, off-the-shelf adoptive cell therapy platform based on gamma-delta T cells, that can be redirected to cancer cell targets with the goal of creating cells with enhanced tumor recognition.
Lead Product(s): Gamma-delta T Cell Adoptive Cell Therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Immatics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
